

Abstract no.: MP. 2-10

10 year review of toxicity of Intravesical Bacillus Calmette-Guérin (IVBCG) therapy for non-muscle invasive bladder cancer (NMIBC) in a single institute.

CC Chan, TY Chan, TK Lo, YK Lee, CH Cheng, SK Chu, CW Man, H Chau

Division of Urology, Department of Surgery

Tuen Mun Hospital, Hong Kong

Objective:

To review the toxicity and compliance of IVBCG therapy in patients suffering from NMIBC.

Patients and methods:

Prospective toxicity data were collected between April 2012 and March 2023 for consecutive patients who were diagnosed with intermediate or high risk NMIBC and received IVBCG therapy.

The IVBCG schedule included a six-week induction course followed by 1-year maintenance course 3-weekly at 3 months, 6 months and 12 months.

Results:

Total 171 patients (141 M; 30 F), with 181 induction and re-induction doses started, were analysed with the mean age of 68 years (age range from 41 to 91).

75 cases (41.4%) completed the planned 1 year maintenance schedule. 104 cases (57.5%) completed 1 year course with omitted dose(s) and/or dose reduction.

Toxicity during the scheduled period are listed below:

	Induction		Maintenance					
			3M		6M		12M	
Number of patients started at least 1 dose	181		154		133		104	
<i>Symptoms</i>								
Dysuria	75	41.40%	79	51.30%	79	59.30%	44	42.30%
Urinary Frequency	70	38.70%	71	46%	66	49.60%	42	40%
Urinary Urgency	58	32.00%	64	41.50%	46	34.60%	32	30.80%
Haematuria	39	21.50%	56	36.40%	30	22.60%	19	18.30%
Fever (>37.5 degrees)	9	5.00%	13	8.40%	11	8%	6	5.80%
Chills	7	3.90%	12	7.80%	9	6.80%	3	2.90%
Unplanned physician attendance	2	1.10%	4	2.60%	3	2.30%	0	0.00%
Number of patients completed all doses in the scheduled period	163	90.00%	131	85.10%	110	82.70%	75	72.10%